PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
-77.00
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.09. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-0.96
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
10.85
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.99. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
15.09%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.54%. Michael Burry would check for aggressive accounting and hidden risks.